Associations Between 25-OH-Vitamin D and COPD Outcomes


In this podcast, Robert Burkes, MD, answers our questions about his team's latest study on the relationship between 25-hydroxyvitamin D (25-OH-vitamin D) and chronic obstructive pulmonary disease (COPD) outcomes, including lung function and exacerbations.

Additional Resources:

  • Burkes RM, Ceppe AS, Doerschuk CM, at al; SPRIOMICS Investigators. Associations among 25-hydroxyvitamin D levels, lung function, and exacerbation outcomes in COPD: an analysis of the SPIROMICS cohort [published online January 17, 2020]. CHEST.
  • Jolliffe DA, Greenberg L, Hooper RL, at al. Vitamin D to prevent exacerbations of COPD: systematic review and meta-analysis of individual participant data from randomised controlled trials. Thorax. 2019;74(4):337-345.
  • Lehouck A, Mathieu C, Carremans C, et al. High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2012;156(2):105-114.
  • Martineau AR, James WY, Hooper RL, at al. Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCo): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med. 2015;3(2):120-130.


Robert M. Burkes, MD, is a clinical instructor and pulmonary research fellow at the University of North Carolina at Chapel Hill.


Submit Feedback